Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib

European Journal of Surgical Oncology

Volumn 39, Issue 9, 2013, Pages 974-980

  Chen, D ^a   Zhao, P ^b   Li, S Q ^a   Xiao, W K ^a   Yin, X Y ^a   Peng, B G ^a   Liang, L J ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b ZUNYI MEDICAL UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Phosphorylated ERK; Prognostic markers; Sorafenib

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; S6 KINASE; SORAFENIB; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; DRUG EFFICACY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT RESPONSE;

HEPATOCELLULAR CARCINOMA; PHOSPHORYLATED ERK; PROGNOSTIC MARKERS; SORAFENIB;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PHOSPHORYLATION; PROGNOSIS; PTEN PHOSPHOHYDROLASE; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; YOUNG ADULT;

EID: 84883775693     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2013.06.018     Document Type: Article

References (22)

1. J.M. Llovet, and J. Bruix Molecular targeted therapies in hepatocellular carcinoma Hepatology 48 4 2008 1312 1327
2. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc Sorafenib in advanced hepatocellular carcinoma The New England Journal of Medicine 359 4 2008 378 390
3. A.L. Cheng, Y.K. Kang, Z. Chen, C.J. Tsao, S. Qin, and J.S. Kim Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial The Lancet Oncology 10 1 2009 25 34
4. S.M. Wilhelm, C. Carter, L. Tang, D. Wilkie, A. McNabola, and H. Rong BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Research 64 19 2004 7099 7109
5. S.M. Wilhelm, L. Adnane, P. Newell, A. Villanueva, J.M. Llovet, and M. Lynch Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling Molecular Cancer Therapeutics 7 10 2008 3129 3140
6. L. Liu, Y. Cao, C. Chen, X. Zhang, A. McNabola, and D. Wilkie Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 Cancer Research 66 24 2006 11851 11858
7. S. Whittaker, R. Marais, and A.X. Zhu The role of signaling pathways in the development and treatment of hepatocellular carcinoma Oncogene 29 36 2010 4989 5005
8. S. Yang, V.C. Ngo, G.B. Lew, L.W. Chong, S.S. Lee, and W.J. Lam AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer Molecular Cancer Therapeutics 8 9 2009 2537 2545
9. A.C. Piguet, B. Saar, R. Hlushchuk, M.V. St-Pierre, and P.M. McSheehy Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma Molecular Cancer Therapeutics 10 6 2011 1007 1017
10. C.L. Sawyers The cancer biomarker problem Nature 452 7187 2008 548 552
11. J.M. Llovet, C.E. Pena, C.D. Lathia, M. Shan, G. Meinhardt, and J. Bruix Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clinical Cancer Research 18 8 2012 2290 2300
12. K. Miyahara, K. Nouso, T. Tomoda, S. Kobayashi, H. Hagihara, and K. Kuwaki Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma Journal of Gastroenterology and Hepatology 26 11 2011 1604 1611
13. G.K. Abou-Alfa, L. Schwartz, S. Ricci, D. Amadori, A. Santoro, and A. Figer Phase II study of sorafenib in patients with advanced hepatocellular carcinoma Journal of Clinical Oncology 24 26 2006 4293 4300
14. Z. Zhang, X. Zhou, H. Shen, D. Wang, and Y. Wang Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study BMC Medicine 7 2009 41 10.1186/1741-7015-7-41
15. J. Bruix, and M. Sherman Management of hepatocellular carcinoma Hepatology 42 5 2005 1208 1236
16. M.S. Choi, Y.H. Shim, J.Y. Hwa, S.K. Lee, J.Y. Ro, and J.S. Kim Expression of DNA methyltransferases in multistep hepatocarcinogenesis Human Pathology 34 1 2003 11 17
17. M. Pinter, W. Sieghart, F. Hucke, I. Graziadei, W. Vogel, and A. Maieron Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib Alimentary Pharmacology & Therapeutics 34 8 2011 949 959
18. M.A. Worns, A. Weinmann, K. Pfingst, C. Schulte-Sasse, C.M. Messow, and H. Schulze-Bergkamen Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis Journal of Clinical Gastroenterology 43 5 2009 489 495
19. J.E. Kim, B.Y. Ryoo, M.H. Ryu, H.M. Chang, D.J. Suh, and H.C. Lee Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function Cancer Chemotherapy and Pharmacology 68 5 2011 1285 1290
20. K.K. Baek, J.H. Kim, J.E. Uhm, S.H. Park, J. Lee, and J.O. Park Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models Oncology 80 3-4 2011 167 174
21. J.H. Shim, J.W. Park, J.I. Choi, B.J. Park, and C.M. Kim Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area Journal of Cancer Research and Clinical Oncology 135 4 2009 617 625
22. E. Christensen Choosing the best endpoint Journal of Hepatology 49 4 2008 672 673